12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether treatment of Rosuvastatin (CRESTOR™) or
Simvastatin given as monotherapy or given in combination with Ezetimibe, will lower the Low
Density Lipoprotein Cholesterol (LDL-C) in patients with Hypercholesterolaemia and Coronary
Heart Disease (CHD) or a CHD Risk Equivalent, Atherosclerosis or a 10-year CHD Risk of >20%